Results of a randomized, placebo‐controlled phase 1b study in MCI and mild AD patients with the orally available PRI‐002 with a unique mode of action.

Abstract

Background: Self‐replicating amyloid beta (Aβ) oligomers are described to be synaptotoxic and responsible for reduced synaptic plasticity, impaired neuronal function and thus for development and progression of Alzheimer’s disease (AD).

The paper